UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Blood, 2021-06, Vol.137 (24), p.3365-3377

2021

Volltextzugriff (PDF)

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma

Journal of hematology and oncology, 2021-08, Vol.14 (1), p.1-132, Article 132

2021

Volltextzugriff (PDF)

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

Clinical cancer research, 2012-05, Vol.18 (9), p.2603-2612

2012

Volltextzugriff (PDF)

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

Blood, 2012-09, Vol.120 (13), p.2679-2689

2012

Volltextzugriff (PDF)

Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function

The Journal of biological chemistry, 2013-02, Vol.288 (8), p.5718-5731

2013

Volltextzugriff (PDF)

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers

NEJM evidence, 2022-01, Vol.1 (1), p.EVIDoa2100001

2022

Volltextzugriff (PDF)

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Nature (London), 2012-05, Vol.485 (7396), p.55-61

2012

Volltextzugriff (PDF)

The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents

Clinical cancer research, 2019-08, Vol.25 (16), p.5167-5176

2019

Volltextzugriff (PDF)

Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.3038-3038

2021

Volltextzugriff (PDF)

Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma

Blood, 2020-11, Vol.136 (Supplement 1), p.33-33

2020

Volltextzugriff (PDF)

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Blood, 2018-11, Vol.132 (Supplement 1), p.1862-1862

2018

Volltextzugriff (PDF)

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

Leukemia, 2013-03, Vol.27 (3), p.586-594

2013

Volltextzugriff (PDF)

Abstract 694: TK-216: a novel, first-in-class, small molecule inhibitor of EWS-FLI1 in early clinical development, for the treatment of Ewing Sarcoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.694-694

2017

Volltextzugriff (PDF)

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Blood, 2019-11, Vol.134 (Supplement_1), p.2856-2856

2019

Volltextzugriff (PDF)

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells

Oncotarget, 2016-08, Vol.7 (34), p.55083-55097

2016

Volltextzugriff (PDF)

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Blood, 2017-12, Vol.130, p.2810-2810

2017

Volltextzugriff (PDF)

Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.408-408

2015

Volltextzugriff (PDF)

Abstract 5179: The first in class FLI1 inhibitor TK-216 presents both in vitro and in vivo anti-tumor activity in lymphoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5179-5179

2017

Volltextzugriff (PDF)

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

Clinical cancer research, 2015-12, Vol.21 (24), p.5499-5510

2015

Volltextzugriff (PDF)

Abstract 2812: mTOR kinase mediates dissemination and colonization of breast cancer metastasis

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2812-2812

2012

Volltextzugriff (PDF)

MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

Blood, 2014-12, Vol.124 (21), p.3613-3613

2014

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(3)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma

Structure-based Design of Pyridone–Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

The translational landscape of mTOR signalling steers cancer initiation and metastasis

The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents

Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)

Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma

Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

Abstract 694: TK-216: a novel, first-in-class, small molecule inhibitor of EWS-FLI1 in early clinical development, for the treatment of Ewing Sarcoma

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer

Abstract 5179: The first in class FLI1 inhibitor TK-216 presents both in vitro and in vivo anti-tumor activity in lymphoma

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

Abstract 2812: mTOR kinase mediates dissemination and colonization of breast cancer metastasis

MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

Suchergebnisse filtern